Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
Recommend:
0
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
Recommend :
0
React to this article
Latest news on REGENERON PHARMACEUTICALS
3d ago REGENERON PHARMACEUTICALS : Patent Issued for VEGF Antagonist Formulations for I..
3d ago REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Report on..
3d ago REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Receives EU Approval fo..
4d ago REGENERON PHARMACEUTICALS : Announces Upcoming 2014 Investor Conference Presenta..
08/13 REGENERON PHARMACEUTICALS : Robbins Arroyo LLP Is Investigating the Officers and..
08/13 REGENERON PHARMACEUTICALS : Patent Issued for Stabilized Formulations Containing..
08/12 REGENERON PHARMACEUTICALS : Financial Results, Study Results, and Proposed Merge..
08/12 REGENERON PHARMACEUTICALS : Bayer Receives EU Approval for EYLEA in Diabetic Mac..
08/11 REGENERON PHARMACEUTICALS : Assigned Patent
08/11 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Receives EU Approval ..
Advertisement
Chart
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
Regeneron Pharmaceuticals  : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF